Defence, Security, Energy, Utilities, Finance, Pharmaceuticals
Home > Pharmaceuticals > North America

Biosimilars & Biobetters USA

16th November to 17th November 2015, Iselin, New Jersey, USA

Overview

Open/Close

The US biosimilars market is expected to reach $1,954 million by 2018 and with the first biosimilar approved recently in America, this is an exciting time for the biosimilar field with approval in the US expected to increase during the next ten years. The regulatory landscape is evolving rapidly so it is important to understand the developments in the biosimilar guideline framework and the cohesion in legislation between the US and Europe.


The learning objectives in the US should be to fully understand the product lifecycle and all aspects of biosimilar research and development.


More information coming soon…

Benefits of Attending

Open/Close

Featured Speakers

Open/Close

Who Should Attend

Open/Close